L30- Antidiabetic Drugs II (insulin secretagogues) Flashcards
Sulfonylureas:
- (1) ultimate goal
- (2) MOA
1- effective reduction of fasting plasma glucose and HbA1c
2- binds to SUR1 subunit –> blocks ATP sensitive K+ channel –> stimulate β-cells
1st generation Sulfonylurea = (1)
- (longer/shorter) 1/2 life than 2nd gen.
- (3) main AE / contraindication
1- chlorpropamide
2- longer (but less potent)
3- hypoglycemia: mostly in elderly, a contraindication
Chlorpropamide
- (1) alcohol association
- potentiates action of (2) hormone
(1st gen. sulfonylurea)
1- hyperemic flush w/ alcohol ingestion; due to inhibition of aldehyde dehydrogenase
2- ADH (vasopressin), especially in SiADH
list the 2nd generation Sulfonylureas
- glyburide (glibenclamide)
- glipizide
- glimepiride
2nd generation Sulfonylureas advantages
-more potent than 1st gen.
-lacks 1st gen. AEs
essentially replaced 1st gen.
2nd generation Sulfonylurea AEs
Glyburide (glibenclamide)- hypoglycemia (20-30% users)
Glipizide: short half-life, lower chance of hypoglycemia (10-15% users)
Glimepiride: hypoglycemia (9-14% users, once a day use)
all Sulfonylurea drugs may cause ______ AEs
- hypoglycemia
- weight gain
list the insulin secretagogues (indicate more effective drug)
- sulfonylureas* (reduces FPG and HbA1c more)
- meglitinides
Meglitinides:
- (1) list drugs
- (2) MOA
1- repaglinide, nateglinide
2- binds SUR1 –> inhibits ATP sensitive K+ channel –> stimulates insulin release
Meglitinides:
- (1) list drugs
- (2) onset speed and duration in comparison with sulfonylureas
- (3) main advantage with sulfonyurea intolerance
- (4) regimen schedule
1- repaglinide, nateglinide
2- rapid onset, short duration
3- no sulfur for allergic patients
4- postprandial glucose regulators –> taken before each meal (omit if meal is missed)
Meglitinides AEs
weight gain
Repaglinide- hypoglycemia
Nateglinide- lower hypoglycemic risk